Larsucosterol Clinical Trials (2026): 1 Studies for Hepatitis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Larsucosterol clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Hepatitis) and 350 total planned enrollment. 1 Phase 3 Larsucosterol trial are listed. 1 Larsucosterol clinical trial is actively recruiting at 5 U.S. sites across 4 states. Most recent activity: NCT07428538 (Feb 2028).
Where to Participate: All Larsucosterol Trial Sites in the U.S. (5 sites across 4 states)
Every actively recruiting Larsucosteroltrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MD | Mercy Medical Center - The Institute for Digestive Health and Liver Disease | Baltimore21202 | NCT07428538 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT07428538 | Map |
| TX | The Liver Institute at Methodist Dallas Medical Center | Dallas75203 | NCT07428538 | Map |
| TX | Baylor College of Medicine (BCM) - Baylor Clinic | Houston77030 | NCT07428538 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT07428538 | Map |
Larsucosterol clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P3 | 1 | 1 |
Recruiting Larsucosterol clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07428538 | AHStudy to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | P3 | Hepatitis | 350 | Jan 2026 |
Larsucosterol pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| AH | NCT07428538 | P3 | recruiting | Hepatitis | 350 | — |
All Larsucosterol trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07428538 | AH | Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | P3 | recruiting | 350 | Bausch Health Americas, Inc. | Jan 2026 |
Larsucosterol clinical trials: frequently asked questions
- How many Larsucosterol clinical trials are there?
- 1 Larsucosterol clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are Larsucosterol clinical trials recruiting in 2026?
- Yes — 1 Larsucosterol trial is actively recruiting in 2026, with 5 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Larsucosterol being studied for?
- Larsucosterol is being studied for Hepatitis. The trials are grouped by indication on this page.
- What phase is Larsucosterol in?
- Larsucosterol clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Larsucosterol clinical trials?
- The lead sponsor across the most Larsucosterol trials is Bausch Health Americas, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Larsucosterolas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: